← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Strykagen Corporation
Reno, NV
$4,128,240
Total funding
5
Grants
Funding over time
peak $994.3K · FY2014–24$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,128,240 · 5
By mechanism
R44$1,953,245 · 1
R42$1,499,996 · 1
R41$674,999 · 3
Investigators at Strykagen Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy$994,272
R44 · FY2024 · OD
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy$958,973
R44 · FY2023 · OD
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy$752,426
R42 · FY2021 · OD
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy$747,570
R42 · FY2020 · OD
Galectin-1 Protein Therapy for Congenital Muscular Dystrophy$225,000
R41 · FY2018 · AR
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy$224,999
R41 · FY2015 · AR
Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy$219,857
R41 · FY2014 · AR
Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy$5,143
R41 · FY2015 · AR